Results 11 to 20 of about 60,158,519 (252)

Interleukin-23 Inhibitors

Turkderm Turkish Archives of Dermatology and Venereology, 2022
For adult patients with moderate to severe plaque psoriasis scheduled for systemic therapy, FDA-approved agents that act via interleukin-23 (IL-23) inhibition are guselkumab, tildrakizumab, and risankizumab.
Esra Adışen
doaj   +2 more sources

The presence, severity, and onset of preeclampsia is associated with maternal interleukin-23 level: A case-control study [PDF]

International Journal of Reproductive BioMedicine, 2023
Background: Scientific evidence support that imbalance between inflammatory and anti-inflammatory cytokines play a critical role in preeclampsia (PE). Objective: To investigate the relationship between the maternal serum level of interleukin (IL)-23, a ...
Forough Forghani, Nasrin Ranjbar, Danial Jahantigh   +2 more
doaj   +2 more sources

Impact of Brucellosis on Interleukin -23 Level, Acid Phosphates and Some Other Trace Elements

Journal of Pure and Applied Microbiology, 2018
The study was carried out during a period of February 2017-July 2018 for the detection of brucellosis in 128 suspected patients with age group range from 17 - 69 years, who attended to Baghdad teaching hospitals, that had been examined and defined as ...
Khalil Ismail A. Mohamed, Wifaq M. Ali Al-Wattar, Ghada Ibrahim Taha, Saad Hasan Mohammed Ali, Huda Q. Mohammed Abu-Al-Ess, Suha A. Al-Fukhar, Jinan M. Mousa   +6 more
doaj   +2 more sources

Efficacy of interleukin-12/23 and interleukin-23 inhibitors in Hailey-Hailey disease [PDF]

JAAD Case Reports
Caroline Echeandia-Francis, BA, Xingyuan Jiang, MD, Ryland D. Mortlock, BS, Mohamad Goldust, MD, Leonard M. Milstone, MD, Keith A. Choate, MD, PhD   +5 more
doaj   +2 more sources

Levels of IL-23/IL-17 Axis in Plasma and Gingival Tissue of Periodontitis Patients According to the New Classification

Applied Sciences, 2022
Background: Periodontitis (P) is a chronic inflammatory disease characterized by the destruction of periodontium support tissue generated by different immuno-inflammatory mechanisms, including the RANK/RANKL/OPG and the IL-23/IL-17 axis.
Ruth Rodríguez-Montaño, Alondra del Carmen Ruiz-Gutiérrez, Vianeth María del Carmen Martínez-Rodríguez, Juan Ramón Gómez-Sandoval, Juan Manuel Guzmán-Flores, Julieta Sarai Becerra-Ruiz, Ana Lourdes Zamora-Perez, Celia Guerrero-Velázquez   +7 more
doaj   +1 more source

Differential regulation of interleukin-17 and interferon-y production in inflammatory bowel disease [PDF]

, 2010
PhDBackground and Aims. Interleukin (IL)-17 is now known to be involved in a number of chronic inflammatory disorders. However, the mechanisms regulating its production in inflammatory bowel disease (IBD) are still unclear. Methods.
Rovedatti, Laura
core   +4 more sources

Circulating Interleukin-23 Levels in Rheumatoid Arthritis and its Relationship to Disease Activity: a Systematic Review with Meta-Analysis

مجله كليه طب الكندي, 2023
Background: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease that is characterized by severe synovial inflammation, cartilage erosion, bone loss, and generalized vasculopathy.
Ahmed Azzam, Shaza Abdul Basset Abdul Basset, Heba Khaled, Neveen Refaey, Ahmed Atta Ahmed Ali, Saad abdelrahim saad shoulah, Mohammed Saleh Al Saifi, Mahmoud s.Meleha   +7 more
doaj   +1 more source

Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis

, 2015
The cytokines interleukin (IL)-12 and interleukin (IL)-23 have been implicated variously in the pathogenesis of psoriasis and psoriatic arthritis (PsA).
McInnes, I.B., Johnsson, H.J.
core   +6 more sources

Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities

Cells, 2020
The interleukin 23 (IL-23) is a key pro-inflammatory cytokine in the development of chronic inflammatory diseases, such as psoriasis, inflammatory bowel diseases, multiple sclerosis, or rheumatoid arthritis.
Gloria Pastor-Fernández, Isabel R. Mariblanca, María N. Navarro   +2 more
doaj   +1 more source

Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data

Научно-практическая ревматология, 2022
Among the pathophysiological mechanisms of immune-mediated inflammatory diseases (IMIDs), specific attention has been paid to the abnormal activation of Th17 type immune response related to the dysregulated synthesis of cytokines forming the interleukin (
E. L. Nasonov, T. V. Korotaeva, S. Rodolfi, C. F. Selmi   +3 more
doaj   +1 more source